# Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV)

> **NCT04525157** · PHASE2 · COMPLETED · sponsor: **Clinuvel Pharmaceuticals Limited** · enrollment: 21 (actual)

## Conditions studied

- Vitiligo

## Interventions

- **DRUG:** Afamelanotide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04525157
- **Lead sponsor:** Clinuvel Pharmaceuticals Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-06
- **Primary completion:** 2016-02-02
- **Final completion:** 2016-06-06
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2023-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04525157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04525157, "Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04525157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*